MedTrace Logo

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00103103 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2010-10-13

No results posted yet for this study

Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with fluorouracil and leucovorin may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving bortezomib together with fluorouracil and leucovorin works in treating patients with metastatic or unresectable stomach cancer.

Conditions

Interventions

DRUG

bortezomib

DRUG

fluorouracil

DRUG

leucovorin calcium

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • California Cancer Consortium

    lead NETWORK

Principal Investigators

  • Heinz-Josef Lenz, MD · University of Southern California

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103103 on ClinicalTrials.gov